Cite
HARVARD Citation
Bensimon, A. et al. (2020). Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Current medical research and opinion. pp. 1507-1517. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bensimon, A. et al. (2020). Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Current medical research and opinion. pp. 1507-1517. [Online].